\-\ Texto\\:\\ \ \(0\)\
\-\ labs\\ were\\ normal\\ except\\ for\\ a\\ small\\ amount\\ of\\ blood\\ in\\ the\\ urine\ \(0\)\
\-\ although\\ intervention\\ with\\ angioplasty\\ was\\ considered\\,\\ it\\ was\\ felt\\ that\\ the\\ risk\\ for\\ further\\ renal\\ injury\\ outweighed\\ any\\ immediate\\ benefits\\ of\\ pta\\,\\ given\\ that\\ hypertension\\ is\\ currently\\ controlled\\ with\\ 2\\ medications\\.\\ he\\ will\\ continue\\ on\\ plavix\\ indefinitely\\ to\\ prevent\\ recurrence\\ of\\ renal\\ infarction\\.\\ should\\ the\\ patient\\ become\\ symptomatic\\ again\\ \\(either\\ infarct\\ or\\ hypertension\\)\\,\\ percutaneous\\ intervention\\ will\\ be\\ reconsidered\\.\ \(0\)\
\-\ ct\\ kub\\ was\\ performed\\ to\\ evaluate\\ for\\ suspected\\ renal\\ stones\\.\\ ct\\ evaluation\\ demonstrated\\ normal\\ appearing\\ kidneys\\,\\ with\\ no\\ evidence\\ of\\ renal\\ obstruction\\ or\\ urolithiasis\\.\\ a\\ recently\\ passed\\ stone\\ was\\ considered\\,\\ and\\ the\\ patient\\ discharged\\ home\\.\ \(0\)\
\-\ the\\ patient\\ returned\\ 4\\ days\\ later\\ with\\ continued\\ and\\ worsening\\ left\\ flank\\ pain\\.\\ there\\ was\\ flank\\ tenderness\\ on\\ physical\\ exam\\.\\ ua\\ showed\\ moderate\\ blood\\.\\ cbc\\ was\\ normal\\,\\ including\\ a\\ normal\\ white\\ count\\.\\ ct\\ kub\\ was\\ again\\ performed\\.\\ there\\ was\\ no\\ urolithiasis\\ or\\ hydronephrosis\\,\\ but\\ there\\ was\\ interval\\ development\\ of\\ significant\\ perinephric\\ stranding\\.\\ given\\ lack\\ of\\ other\\ clinical\\ findings\\ of\\ pyelonephritis\\,\\ a\\ renal\\ mass\\ could\\ not\\ be\\ excluded\\,\\ and\\ a\\ contrast\\ examination\\ was\\ ordered\\.\ \(0\)\
\-\ contrast\\ ct\\ demonstrated\\ a\\ wedge\\ shaped\\ area\\ of\\ non\\-perfusion\\ in\\ the\\ upper\\ outer\\ aspect\\ of\\ the\\ left\\ kidney\\.\\ a\\ renal\\ infarct\\ was\\ felt\\ to\\ be\\ the\\ most\\ likely\\ etiology\\,\\ though\\ there\\ was\\ no\\ history\\ to\\ suggest\\ a\\ source\\.\\ further\\ evaluation\\ included\\ echocardiography\\,\\ which\\ was\\ negative\\.\\ laboratory\\ analysis\\ for\\ abnormal\\ clotting\\ factors\\ was\\ negative\\.\\ as\\ fibromuscular\\ dysplasia\\ and\\ vasculitis\\ were\\ also\\ considered\\,\\ renal\\ mra\\ performed\\.\\ this\\ again\\ demonstrated\\ the\\ area\\ of\\ non\\-perfusion\\ in\\ the\\ left\\ kidney\\,\\ but\\ also\\ showed\\ irregular\\ narrowing\\ and\\ dilation\\ of\\ both\\ renal\\ arteries\\,\\ highly\\ suggest\\ of\\ fibromuscular\\ dysplasia\\.\ \(0\)\
\-\ the\\ patient\\ was\\ treated\\ for\\ symptoms\\ and\\ placed\\ on\\ plavix\\.\\ outpatient\\ angiography\\ was\\ then\\ performed\\,\\ confirming\\ findings\\ of\\ fmd\\ previously\\ seen\\ on\\ mr\ \(0\)\
\-\ fibromuscular\\ dysplasia\\,\\ renal\\ infarct\ \(0\)\
\-\ initial\\ appearance\\ of\\ the\\ kidney\\:\ \(0\)\
\-\ pyelonephritis\ \(60\)\
\-\ renal\\ infarct\ \(6\)\
\-\ renal\\ neoplasm\\ \\(rcc\\,\\ aml\\)\\,\\ possibly\\ with\\ acute\\ hemorrhage\ \(0\)\
\-\ for\\ renal\\ artery\\ changes\\:\ \(0\)\
\-\ atherosclerotic\\ disease\ \(11\)\
\-\ fibromuscular\\ dysplasia\ \(11\)\
\-\ vasculitis\ \(67\)\
\-\ trauma\ \(1087\)\
\-\ 38\\ year\\ old\\ healthy\\ male\\ with\\ past\\ medical\\ history\\ significant\\ only\\ for\\ recent\\ onset\\ hypertension\\.\\ presented\\ to\\ the\\ emergency\\ department\\ with\\ acute\\ onset\\ of\\ left\\ flank\\ pain\\.\ \(0\)\
\-\ this\\ patient\\â\\€\\™s\\ demographics\\ and\\ presentation\\ where\\ somewhat\\ atypically\\,\\ but\\ demonstrate\\ the\\ need\\ for\\ proper\\ differential\\ diagnoses\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ renal\\:\\ 0\\.3847838370106472\ \(0\)\
\-\ was\\:\\ 0\\.28712572483604487\ \(0\)\
\-\ fibromuscular\\:\\ 0\\.2354106157067266\ \(0\)\
\-\ infarct\\:\\ 0\\.1713907139705452\ \(0\)\
\-\ dysplasia\\:\\ 0\\.15774834298635465\ \(0\)\
\-\ of\\:\\ 0\\.1511503871463647\ \(0\)\
\-\ the\\:\\ 0\\.14384236342323495\ \(0\)\
\-\ urolithiasis\\:\\ 0\\.1396654183198397\ \(0\)\
\-\ again\\:\\ 0\\.13779134976928825\ \(0\)\
\-\ flank\\:\\ 0\\.13549504698639483\ \(0\)\
\-\ plavix\\:\\ 0\\.1323453814976809\ \(0\)\
\-\ for\\:\\ 0\\.12485384702682394\ \(0\)\
\-\ performed\\:\\ 0\\.1218505674183417\ \(0\)\
\-\ considered\\:\\ 0\\.12037203874366939\ \(0\)\
\-\ hypertension\\:\\ 0\\.11819478330434317\ \(0\)\
\-\ kub\\:\\ 0\\.11641522829494398\ \(0\)\
\-\ kidney\\:\\ 0\\.10852435306155102\ \(0\)\
\-\ pyelonephritis\\:\\ 0\\.1069457613938172\ \(0\)\
\-\ vasculitis\\:\\ 0\\.09557267180754624\ \(0\)\
\-\ demonstrated\\:\\ 0\\.09493619033319667\ \(0\)\
\-\ felt\\:\\ 0\\.0904774070990819\ \(0\)\
\-\ intervention\\:\\ 0\\.08650818896251532\ \(0\)\
\-\ normal\\:\\ 0\\.08409481914114333\ \(0\)\
\-\ patient\\:\\ 0\\.0837382812934645\ \(0\)\
\-\ suggest\\:\\ 0\\.08365749733268117\ \(0\)\
\-\ there\\:\\ 0\\.0819535073995464\ \(0\)\
\-\ reconsidered\\:\\ 0\\.07868637634942934\ \(0\)\
\-\ ct\\:\\ 0\\.07841345329536385\ \(0\)\
\-\ but\\:\\ 0\\.0763881381577432\ \(0\)\
\-\ atypically\\:\\ 0\\.07608955196021429\ \(0\)\
\-\ and\\:\\ 0\\.07448086658314236\ \(0\)\
\-\ indefinitely\\:\\ 0\\.0740752984775058\ \(0\)\
\-\ outweighed\\:\\ 0\\.0724295335491349\ \(0\)\
\-\ given\\:\\ 0\\.07084207603718856\ \(0\)\
\-\ with\\:\\ 0\\.07057899308444482\ \(0\)\
\-\ left\\:\\ 0\\.07025973065922021\ \(0\)\
\-\ fmd\\:\\ 0\\.06876951513805549\ \(0\)\
\-\ showed\\:\\ 0\\.06859418997982725\ \(0\)\
\-\ further\\:\\ 0\\.06707478077174946\ \(0\)\
\-\ area\\:\\ 0\\.0667141008743676\ \(0\)\
\-\ will\\:\\ 0\\.06628283660230655\ \(0\)\
\-\ pta\\:\\ 0\\.06617269074884045\ \(0\)\
\-\ onset\\:\\ 0\\.06612853282399267\ \(0\)\
\-\ clotting\\:\\ 0\\.06478121632856144\ \(0\)\
\-\ to\\:\\ 0\\.06436408541779923\ \(0\)\
\-\ demographics\\:\\ 0\\.06415843726613195\ \(0\)\
\-\ negative\\:\\ 0\\.06375628536532035\ \(0\)\
\-\ evaluation\\:\\ 0\\.06280502167959738\ \(0\)\
\-\ be\\:\\ 0\\.06266433952948786\ \(0\)\
\-\ on\\:\\ 0\\.06220547624264629\ \(0\)\
\-\ aml\\:\\ 0\\.062024622882141\ \(0\)\
\-\ rcc\\:\\ 0\\.06070127494432701\ \(0\)\
\-\ blood\\:\\ 0\\.059808796182061634\ \(0\)\
\-\ benefits\\:\\ 0\\.0595473593942084\ \(0\)\
\-\ significant\\:\\ 0\\.05946031525374839\ \(0\)\
\-\ angioplasty\\:\\ 0\\.05820761414747199\ \(0\)\
\-\ echocardiography\\:\\ 0\\.0579015944658375\ \(0\)\
\-\ perinephric\\:\\ 0\\.05760561004491376\ \(0\)\
\-\ confirming\\:\\ 0\\.05760561004491376\ \(0\)\
\-\ proper\\:\\ 0\\.056255829537466606\ \(0\)\
\-\ acute\\:\\ 0\\.05571005282158445\ \(0\)\
\-\ passed\\:\\ 0\\.05530477007662246\ \(0\)\
\-\ atherosclerotic\\:\\ 0\\.05508187687350546\ \(0\)\
\-\ diagnoses\\:\\ 0\\.054444432144032565\ \(0\)\
\-\ wedge\\:\\ 0\\.05384904829558817\ \(0\)\
\-\ or\\:\\ 0\\.05373910838008285\ \(0\)\
\-\ controlled\\:\\ 0\\.05365900514825156\ \(0\)\
\-\ were\\:\\ 0\\.053084939055112766\ \(0\)\
\-\ outpatient\\:\\ 0\\.05276453970401015\ \(0\)\
\-\ mra\\:\\ 0\\.05092222886913109\ \(0\)\
\-\ findings\\:\\ 0\\.050826411851225\ \(0\)\
\-\ excluded\\:\\ 0\\.05064867108354351\ \(0\)\
\-\ continue\\:\\ 0\\.05051493951046603\ \(0\)\
\-\ no\\:\\ 0\\.050233518366546805\ \(0\)\
\-\ contrast\\:\\ 0\\.05003750508339169\ \(0\)\
\-\ percutaneous\\:\\ 0\\.049630498182834555\ \(0\)\
\-\ outer\\:\\ 0\\.04951093728155211\ \(0\)\
\-\ immediate\\:\\ 0\\.0492764639407602\ \(0\)\
\-\ ua\\:\\ 0\\.04916147237193655\ \(0\)\
\-\ source\\:\\ 0\\.049047927276328014\ \(0\)\
\-\ stones\\:\\ 0\\.048607512316893156\ \(0\)\
\-\ also\\:\\ 0\\.04844041444695737\ \(0\)\
\-\ returned\\:\\ 0\\.04839510919755941\ \(0\)\
\-\ possibly\\:\\ 0\\.04839510919755941\ \(0\)\
\-\ except\\:\\ 0\\.04798473325446366\ \(0\)\
\-\ analysis\\:\\ 0\\.04788498952048119\ \(0\)\
\-\ hydronephrosis\\:\\ 0\\.04778633590377312\ \(0\)\
\-\ angiography\\:\\ 0\\.04759220549529372\ \(0\)\
\-\ need\\:\\ 0\\.04740216234795712\ \(0\)\
\-\ prevent\\:\\ 0\\.04721603789661415\ \(0\)\
\-\ stone\\:\\ 0\\.047033673793619515\ \(0\)\
\-\ somewhat\\:\\ 0\\.04685492109938663\ \(0\)\
\-\ interval\\:\\ 0\\.04659325883418465\ \(0\)\
\-\ urine\\:\\ 0\\.046091645565224174\ \(0\)\
\-\ stranding\\:\\ 0\\.046091645565224174\ \(0\)\
\-\ highly\\:\\ 0\\.046091645565224174\ \(0\)\
\-\ become\\:\\ 0\\.045693928546883096\ \(0\)\
\-\ 38\\:\\ 0\\.045693928546883096\ \(0\)\
\-\ home\\:\\ 0\\.04553962195040694\ \(0\)\
\-\ dilation\\:\\ 0\\.04531299792843972\ \(0\)\
\-\ ordered\\:\\ 0\\.04523870354954095\ \(0\)\
\-\ recently\\:\\ 0\\.04494749390581376\ \(0\)\
\-\ though\\:\\ 0\\.04473509078648002\ \(0\)\
\-\ that\\:\\ 0\\.04469091005420466\ \(0\)\
\-\ included\\:\\ 0\\.04452757093265872\ \(0\)\
\-\ kidneys\\:\\ 0\\.04432471484338426\ \(0\)\
\-\ discharged\\:\\ 0\\.04419196662627263\ \(0\)\
\-\ lack\\:\\ 0\\.04406114236421269\ \(0\)\
\-\ healthy\\:\\ 0\\.0436796750641746\ \(0\)\
\-\ factors\\:\\ 0\\.04355601948553475\ \(0\)\
\-\ department\\:\\ 0\\.04355601948553475\ \(0\)\
\-\ medications\\:\\ 0\\.04319490268830723\ \(0\)\
\-\ shaped\\:\\ 0\\.04301962114046575\ \(0\)\
\-\ cbc\\:\\ 0\\.042961942247222135\ \(0\)\
\-\ either\\:\\ 0\\.04256819127291657\ \(0\)\
\-\ development\\:\\ 0\\.04256819127291657\ \(0\)\
\-\ recurrence\\:\\ 0\\.042513317449950225\ \(0\)\
\-\ count\\:\\ 0\\.042513317449950225\ \(0\)\
\-\ suspected\\:\\ 0\\.04219090045939331\ \(0\)\
\-\ continued\\:\\ 0\\.04219090045939331\ \(0\)\
\-\ etiology\\:\\ 0\\.041480567693300635\ \(0\)\
\-\ previously\\:\\ 0\\.04133536269499928\ \(0\)\
\-\ amount\\:\\ 0\\.04119245655336413\ \(0\)\
\-\ appearing\\:\\ 0\\.041145319547662665\ \(0\)\
\-\ arteries\\:\\ 0\\.04086755252157932\ \(0\)\
\-\ where\\:\\ 0\\.040466299081614324\ \(0\)\
\-\ infarction\\:\\ 0\\.040422796751250704\ \(0\)\
\-\ placed\\:\\ 0\\.040124012914556466\ \(0\)\
\-\ evaluate\\:\\ 0\\.04004043161296647\ \(0\)\
\-\ narrowing\\:\\ 0\\.03991649306073517\ \(0\)\
\-\ irregular\\:\\ 0\\.03975384512738366\ \(0\)\
\-\ symptomatic\\:\\ 0\\.039594076070178265\ \(0\)\
\-\ currently\\:\\ 0\\.03955457177920788\ \(0\)\
\-\ history\\:\\ 0\\.03934559988753479\ \(0\)\
\-\ worsening\\:\\ 0\\.039321109212290775\ \(0\)\
\-\ moderate\\:\\ 0\\.038654901688180275\ \(0\)\
\-\ in\\:\\ 0\\.03842837131360525\ \(0\)\
\-\ emergency\\:\\ 0\\.03820260164989926\ \(0\)\
\-\ could\\:\\ 0\\.03745401266130665\ \(0\)\
\-\ laboratory\\:\\ 0\\.03739175920021996\ \(0\)\
\-\ pain\\:\\ 0\\.0368512310601737\ \(0\)\
\-\ later\\:\\ 0\\.03684999366675801\ \(0\)\
\-\ including\\:\\ 0\\.03684999366675801\ \(0\)\
\-\ risk\\:\\ 0\\.03679175658682284\ \(0\)\
\-\ then\\:\\ 0\\.036450010432392745\ \(0\)\
\-\ obstruction\\:\\ 0\\.036067001388747556\ \(0\)\
\-\ labs\\:\\ 0\\.03567390374314922\ \(0\)\
\-\ presentation\\:\\ 0\\.035446008203478825\ \(0\)\
\-\ this\\:\\ 0\\.03538693220518747\ \(0\)\
\-\ neoplasm\\:\\ 0\\.035150830423552853\ \(0\)\
\-\ although\\:\\ 0\\.035054544539097295\ \(0\)\
\-\ recent\\:\\ 0\\.03486500022937677\ \(0\)\
\-\ initial\\:\\ 0\\.03454258323881986\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.03447496707187522\ \(0\)\
\-\ white\\:\\ 0\\.03397274694446014\ \(0\)\
\-\ should\\:\\ 0\\.033598313335332\ \(0\)\
\-\ injury\\:\\ 0\\.033577959964635286\ \(0\)\
\-\ past\\:\\ 0\\.03351717376806336\ \(0\)\
\-\ differential\\:\\ 0\\.03345679417116627\ \(0\)\
\-\ mr\\:\\ 0\\.03331745951371892\ \(0\)\
\-\ any\\:\\ 0\\.03327804147693339\ \(0\)\
\-\ aspect\\:\\ 0\\.03321923530100587\ \(0\)\
\-\ examination\\:\\ 0\\.03294976107851874\ \(0\)\
\-\ medical\\:\\ 0\\.03272501794895206\ \(0\)\
\-\ clinical\\:\\ 0\\.03263300169772373\ \(0\)\
\-\ days\\:\\ 0\\.03259645623857637\ \(0\)\
\-\ tenderness\\:\\ 0\\.03229165235815318\ \(0\)\
\-\ only\\:\\ 0\\.03216907625047465\ \(0\)\
\-\ treated\\:\\ 0\\.032065319750887264\ \(0\)\
\-\ artery\\:\\ 0\\.031979757820418314\ \(0\)\
\-\ changes\\:\\ 0\\.031119419887828417\ \(0\)\
\-\ appearance\\:\\ 0\\.03104233388494586\ \(0\)\
\-\ abnormal\\:\\ 0\\.03093550759581024\ \(0\)\
\-\ likely\\:\\ 0\\.030770150970441525\ \(0\)\
\-\ he\\:\\ 0\\.030491481227613627\ \(0\)\
\-\ presented\\:\\ 0\\.030027027063346434\ \(0\)\
\-\ trauma\\:\\ 0\\.029904398091030817\ \(0\)\
\-\ evidence\\:\\ 0\\.02922675067363964\ \(0\)\
\-\ both\\:\\ 0\\.028714285947098704\ \(0\)\
\-\ symptoms\\:\\ 0\\.02817332658122648\ \(0\)\
\-\ physical\\:\\ 0\\.02791996709433902\ \(0\)\
\-\ upper\\:\\ 0\\.027516352555754815\ \(0\)\
\-\ most\\:\\ 0\\.026797825826555665\ \(0\)\
\-\ demonstrate\\:\\ 0\\.026769093549523604\ \(0\)\
\-\ other\\:\\ 0\\.026740452437987013\ \(0\)\
\-\ small\\:\\ 0\\.026561139060746423\ \(0\)\
\-\ it\\:\\ 0\\.026357867673177413\ \(0\)\
\-\ exam\\:\\ 0\\.025920933900087133\ \(0\)\
\-\ seen\\:\\ 0\\.024241862690273494\ \(0\)\
\-\ which\\:\\ 0\\.02341377599239286\ \(0\)\
\-\ male\\:\\ 0\\.02292607357800927\ \(0\)\
\-\ disease\\:\\ 0\\.021614375033815893\ \(0\)\
\-\ as\\:\\ 0\\.020686032468857574\ \(0\)\
\-\ not\\:\\ 0\\.020327687608290443\ \(0\)\
\-\ mass\\:\\ 0\\.019668444471509377\ \(0\)\
\-\ year\\:\\ 0\\.01586871980790848\ \(0\)\
\-\ old\\:\\ 0\\.01523946410927342\ \(0\)\
\-\ is\\:\\ 0\\.014101344462492544\ \(0\)\
